1. Home
  2. COGT vs TSLX Comparison

COGT vs TSLX Comparison

Compare COGT & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • TSLX
  • Stock Information
  • Founded
  • COGT 2014
  • TSLX 2010
  • Country
  • COGT United States
  • TSLX United States
  • Employees
  • COGT N/A
  • TSLX N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • TSLX Investment Managers
  • Sector
  • COGT Health Care
  • TSLX Finance
  • Exchange
  • COGT Nasdaq
  • TSLX Nasdaq
  • Market Cap
  • COGT 2.3B
  • TSLX 2.2B
  • IPO Year
  • COGT 2018
  • TSLX 2014
  • Fundamental
  • Price
  • COGT $36.63
  • TSLX $21.33
  • Analyst Decision
  • COGT Buy
  • TSLX Buy
  • Analyst Count
  • COGT 13
  • TSLX 10
  • Target Price
  • COGT $28.08
  • TSLX $23.50
  • AVG Volume (30 Days)
  • COGT 4.8M
  • TSLX 525.5K
  • Earning Date
  • COGT 11-03-2025
  • TSLX 11-04-2025
  • Dividend Yield
  • COGT N/A
  • TSLX 9.90%
  • EPS Growth
  • COGT N/A
  • TSLX N/A
  • EPS
  • COGT N/A
  • TSLX 2.04
  • Revenue
  • COGT N/A
  • TSLX $464,512,000.00
  • Revenue This Year
  • COGT N/A
  • TSLX N/A
  • Revenue Next Year
  • COGT N/A
  • TSLX N/A
  • P/E Ratio
  • COGT N/A
  • TSLX $10.40
  • Revenue Growth
  • COGT N/A
  • TSLX N/A
  • 52 Week Low
  • COGT $3.72
  • TSLX $18.58
  • 52 Week High
  • COGT $37.08
  • TSLX $25.17
  • Technical
  • Relative Strength Index (RSI)
  • COGT 83.97
  • TSLX 45.25
  • Support Level
  • COGT $32.85
  • TSLX $20.68
  • Resistance Level
  • COGT $36.29
  • TSLX $21.16
  • Average True Range (ATR)
  • COGT 2.62
  • TSLX 0.48
  • MACD
  • COGT 1.10
  • TSLX -0.03
  • Stochastic Oscillator
  • COGT 98.45
  • TSLX 36.21

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

Share on Social Networks: